CagriSema misses non-inferiority against tirzepatide in head-to-head trial
Novo Nordisk's cagrilintide-semaglutide combination produced 23% weight loss at 84 weeks versus 25.5% for tirzepatide in an open-label study.
PR
By Priya Raman · Science Reporter
Feb 26 03:00 ETSource: drugdiscoverytrends.com
The wire
- 01Novo Nordisk said CagriSema failed its primary non-inferiority endpoint, with 23% weight loss at 84 weeks against 25.5% for tirzepatide; the stock fell 16% that afternoon.
- 02Prescribers weighing future combination options now have a direct comparison, with gastrointestinal adverse events described as mostly mild to moderate.
- 03Novo executives attributed the comparator's performance partly to the open-label design and investigator familiarity; FDA decision is expected late 2026, with REDEFINE 11 and a higher-dose trial to come.
From the source
Read at drugdiscoverytrends.comNovo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to tirzepatide, the company announced on Monday.